Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of VLA15 Lyme disease vaccine in participants aged 5 years and older
NL-OMON56314Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Lyme borreliosis comparing VLA15 vaccine with Placebo (2 arms). Primary endpoints: Vaccine efficacy after booster dose, Local reactions and 5 more. Started Sep 2022; status: recruiting.
02
Drugs
Lyme Disease Vaccine Recombinant OspA
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on NL-OMON56314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56314.